Study of Decitabine, Venetoclax, and Olutasidenib for IDH1-Mutated Myeloid Cancers
This study is testing a combination of three drugs: decitabine (given by IV or orally as decitabine/cedazuridine), venetoclax, and olutasidenib. Olutasidenib is a targeted inhibitor for the IDH1 gene mutation. The study aims to find a safe and effective dose of these drugs for people with specific blood cancers, including relapsed or refractory (meaning it came back or didn't respond to previous treatment) Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS). You can join if you are over 18 and have a documented IDH1 gene mutation. The main goal is to see how safe the drug combination is and how many people experience a complete or partial remission. The study plans to enroll 78 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It aims to enroll 78 participants to determine the best dose and effectiveness of the drug combination.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
At a glance
Conditions
Where it's being run
5 sites across 5 statesStudy leadership
- Courtney DiNardo, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0